Nurix Therapeutics Valuation Multiples

Nurix Therapeutics Overview

About Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Founded

2009

HQ

Employees

317

Website

nurixtx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $75M

EBITDA: ($293M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Nurix Therapeutics Financials

Nurix Therapeutics reported last 12-month revenue of $75M and negative EBITDA of ($293M).

In the same LTM period, Nurix Therapeutics generated $75M in gross profit, ($293M) in EBITDA losses, and had net loss of ($289M).

Nurix Therapeutics P&L

In the most recent fiscal year, Nurix Therapeutics reported revenue of $84M and EBITDA of ($264M).

Nurix Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nurix Therapeutics Stock Performance

Nurix Therapeutics has current market cap of $2B, and enterprise value of $1B.

Nurix Therapeutics' stock price is $16.24.

Nurix Therapeutics Valuation Multiples

Nurix Therapeutics trades at 16.1x EV/Revenue multiple, and (4.1x) EV/EBITDA.

Nurix Therapeutics Financial Valuation Multiples

As of April 11, 2026, Nurix Therapeutics has market cap of $2B and EV of $1B.

Equity research analysts estimate Nurix Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nurix Therapeutics has a P/E ratio of (5.8x).

Nurix Therapeutics Margins & Growth Rates

Nurix Therapeutics' revenue in the last 12 month declined by (14%).

Nurix Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.2M for the same period.

Nurix Therapeutics' rule of 40 is (612%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nurix Therapeutics' rule of X is (653%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Nurix Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Nurix Therapeutics M&A Activity

Nurix Therapeutics acquired XXX companies to date.

Last acquisition by Nurix Therapeutics was on XXXXXXXX, XXXXX. Nurix Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nurix Therapeutics Investment Activity

Nurix Therapeutics invested in XXX companies to date.

Nurix Therapeutics made its latest investment on XXXXXXXX, XXXXX. Nurix Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).